Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination With Anti-PD-1 Therapy (AB122) in Patients With Advanced Dedifferentiated Liposarcoma

NCT05886634 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT05886634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05886634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination With Anti-PD-1 Therapy (AB122) in Patients With Advanced Dedifferentiated Liposarcoma
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 23, 2023
Completion date
May 23, 2027
Enrollment
16 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

dedifferentiated liposarcoma, metastatic dedifferentiated liposarcoma, recurrent dedifferentiated liposarcoma, sarcoma, sarcoma,soft tissue, soft tissue sarcoma, unresectable dedifferentiated liposarcoma